Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2011

View Archived Issues

Phase III briakinumab data analyzed

Scientists at Astellas Pharma synthesize novel plasma kallikrein inhibitors

Phase II studies assess NGR-hTNF in lung and ovarian cancer

Novel TRPV4 antagonists prepared by researchers at GlaxoSmithKline

Phase III trial of cabozantinib meets primary endpoint

RetroSense Therapeutics licenses gene therapy from Wayne State University

EMA begins new review of Protelos and Osseor

Qutenza shows efficacy in HIV-associated neuropathy

New data presented from CARE-MS trials of alemtuzumab

Novel omega-3 MUFAs show oncolytic potential

Precision Antibody receives FDA contract to develop potency assays for influenza vaccine

TiGenix moves into randomized recruitment stage in phase Ia/IIb Cx-611 study

Merck Frosst discloses new HIV reverse transcriptase inhibitors

California Stem Cell acquires stem cell therapy program for metastatic melanoma

Basilea finishes multiple-ascending-dose study of antibiotic BAL-30072

Italian researchers prepare novel TRPV1 antagonists

New glucagon receptor antagonists designed by Merck & Co.

CDC advisory committee recommends Merck & Co.'s HPV vaccine for boys and young men

Lilly withdraws Xigris worldwide following PROWESS-SHOCK study

Bayer's phase III CORRECT trial meets primary endpoint

Elusys initiates new human safety study of anthrax treatment candidate

FDA provides update on safety review of Chantix

FDA grants IND clearance for phase II trial of Aeterna Zentaris' AEZS-108 in breast cancer

Seattle Genetics starts new Adcetris trial in nonlymphoma malignancies

DelMar Pharmaceuticals commences phase I/II trial of VAL-083

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...